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AntiviralsNipah virus (NiV) is a zoonotic biosafety level 4 paramyxovirus that emerged recently in Asia with high
mortality in man. NiV is a member, with Hendra virus (HeV), of the Henipavirus genus in the
Paramyxoviridae family. Although NiV entry, like that of other paramyxoviruses, is believed to occur via
pH-independent fusion with the host cell's plasma membrane we present evidence that entry can occur by
an endocytic pathway. The NiV receptor ephrinB2 has receptor kinase activity and we ﬁnd that ephrinB2's
cytoplasmic domain is required for entry but is dispensable for post-entry viral spread. The mutation of a
single tyrosine residue (Y304F) in ephrinB2's cytoplasmic tail abrogates NiV entry. Moreover, our results
show that NiV entry is inhibited by constructions and drugs speciﬁc for the endocytic pathway of
macropinocytosis. Our ﬁndings could potentially permit the rapid development of novel low-cost antiviral
treatments not only for NiV but also HeV.
© 2009 Elsevier Inc. All rights reserved.Introduction
The zoonotic biosafety level 4 (BSL-4) pathogens Nipah virus (NiV)
and Hendra virus (HeV) are the sole members of the Henipavirus
genus in the Paramyxoviridae family. NiV ﬁrst emerged 10 years ago
in Malaysia from its reservoir the Pteropus fruit bat, infecting
successively pigs and humans. When the virus ﬁrst emerged, NiV-
induced encephalitis was responsible for a mortality rate of 40% but
latterly annual NiV outbreaks in Bangladesh have occurred in which
no intermediate host has been identiﬁed and the mortality rate has
almost doubled. At present, no antiviral treatments or prophylaxis are
available to combat NiV infection. Gaining a better understanding of
NiV entry into the host cell is crucial if antivirals inhibiting this process
and hence infection are to be identiﬁed.
The entry of enveloped viruses into the host cell is believed to
occur either by pH-independent fusion of the virion envelopewith the
plasma membrane or by endocytosis. In the latter case, the acidic pH
of the endosome is thought to trigger conformational changes in the
fusion protein leading to fusion of the virion and endosomal
membranes (Earp et al., 2004). NiV entry has been assumed to
occur by the former mechanism, mediated by the concerted action of
the viral glycoproteins following receptor attachment. NiV uses both
ephrinB2 and ephrinB3 – ligands for members of the EphB class of
receptor tyrosine kinases (RTKs) – as receptors for entry (Bonaparte
et al., 2005; Negrete et al., 2005, 2006). Importantly, ephrinB2 and
ephrinB3 also possess RTK activity. Ephs and ephrins are plasma
membrane-bound proteins and consistent with NiV's tropism,nd).
ll rights reserved.ephrinB2 is expressed on vascular endothelial cells and neurons
whereas ephrinB3 expression is limited to cells in particular areas of
the CNS such as the corpus callosum and the spinal cord.
Although the entry of paramyxoviruses such as NiV has been
considered to occur exclusively by fusion at the plasma membrane
(Lamb and Kolakofsky, 2001), two recent studies (Cantin et al., 2007;
Kolokoltsov et al., 2007) suggest that endocytosis can also play a role
in the entry of two paramyxoviruses: caveolae-dependent endocyto-
sis in the case of Newcastle disease virus (NDV) and clathrin-
dependent endocytosis for respiratory syncytial virus (RSV). Recently,
vaccinia virus, the prototype of the family Poxviridae, and human
adenovirus of the family Adenoviridae have been shown to use
macropinocytosis for entry (Amstutz et al., 2008; Mercer and
Helenius, 2008). Constitutive macropinocytosis is an active endocytic
pathway occurring in macrophages and immature dendritic cells,
which serves to take up ﬂuid and exogenous antigens from the
extracellular milieu but is also implicated in cell migration (for a
review see (Conner and Schmid, 2002; Klasse et al., 1998). In many
other cell types macropinocytosis can be induced transiently by
interaction of receptors with speciﬁc ligands. For example, binding of
epidermal growth factor (EGF) to its receptor EGFR induces rapid
internalization of both proteins and intracellular sorting to the
lysosomes by a kinase-dependent pathway (Kornilova et al., 1996).
Moreover, macropinocytosis occurs in regions of the plasma
membrane where the formation of lamellipodia and ﬁlopodia is
taking place (for a review, see Klasse et al., 1998). A recent review on
viral entry by macropinocytosis (Mercer and Helenius, 2009)
discusses the molecular machinery involved in this endocytic
pathway and the criteria by which it can be characterized. Here, we
show that both in Vero cells and CHO-K1 cells expressing human
ephrinB2, entry by the paramyxovirus NiV occurs not by fusion at the
Fig. 1. ephrinB2 induces ﬁlopodia formation. CHO cells were transfected with either 1 μg of peGFP-N1 (A) or 1 μg of peGFP-N1-ephrinB2 (B) and observed by conventional
ﬂuorescent microscopy.
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deﬁning macropinocytosis.
Results
ephrinB2 induces ﬁlopodia formation and is endocytosed by NiV-G
The original aim of this study was to investigate whether ephrinB2
is downregulated from the cell surface upon infection. We had
previously mapped the ephrinB2 binding site on the NiV-G globular
head (Guillaume et al., 2006) and endeavored to map the NiV-G
binding site on ephrinB2 by using receptor downregulation as a
handle. We anticipated that ephrinB2 could be downregulated by
NiV-G because members of the Morbillivirus genus, the only
paramyxovirus genus other than the Henipaviruses to use cellular
proteins as receptors rather than sialic acid, internalize their receptors
upon infection. A major problem in studying ephrinB2 downregula-
tion is the lack of an adequate α-human-ephrinB2 antibody, probably
explained by the very high level of conservation between human and
murine ephrinB2. To overcome this difﬁculty, we used a recombinant
system tagging human ephrinB2 with eGFP by subcloning the
ephrinB2 gene into the peGFP-N1 expression vector that we used to
transfect (ephrinB2-negative) CHO-K1 cells. In contrast to the
expression of eGFP (Fig. 1A), we found that the expression of
ephrinB2-eGFP induced the formation of multiple extended ramiﬁed
ﬁlopodia (Fig. 1B). This ﬁnding is in agreement with a previous report
that expression of murine ephrinB2 in B16 melanoma cells induces
the formation of ﬁlopodia thereby enhancing cell migration (Meyer
et al., 2005).
Using confocal microscopy analysis, we found that when ephrinB2
tagged with eGFP (green) was co-expressed with mRFP (red) in CHO-
K1 cells, the ephrinB2 was present in the plasma membrane, in
particular at the level of the numerous ﬁlopodia, but there was no
colocalization with mRFP whose expression was cytoplasmic (Fig. 2A,
top). However, when ephrinB2.eGFP was co-expressed with NiV-G.
mRFP, the two proteins were endocytosed, colocalizing in intracellu-
lar vesicles and the number of ﬁlopodia appeared to be reduced
(Fig. 2A, middle). Expression of mRFP-tagged NiV-G was veriﬁed by
ﬂow cytometry and its fusion promotion capacity by co-expression
with NiV-F (Figs. S1A and B). Furthermore, soluble murine EphB4-Fc
was used to demonstrate that its surface expression was equivalent to
that of non-tagged ephrinB2 (Fig. S3). As our previous results had
shown that residue E533 of NiV-G is crucial for the interaction with
ephrinB2 (Guillaume et al., 2006), we also co-expressed the NiV-G.
E533Q.mRFPmutant with ephrinB2.eGFP. In this case, smaller vesicles
with much lower levels of colocalization were observed and the
number of ﬁlopodia appeared to be unaffected (Fig. 2A bottom).
As these results appear to show that ephrinB2 is endocytosed from
the cell surface following contact with NiV-G, we began to consider
the possibility that the whole virus could enter the host cell by thesame mechanism. Thus, it was important to determine whether
intracellular vesicles were also formed when ephrinB2 and NiV-G
were expressed on opposing cells. For this, cocultures were made of
NiV-G-expressing CHO cells with CHO cells expressing either eGFP or
ephrinB2.eGFP. Evenwhen in close proximity, therewas no transfer of
NiV-G to eGFP-expressing CHO cells (Fig. 2B, top). In contrast, in
cocultures of NiV-G- and ephrinB2-expressing CHO-K1 cells both
proteins were found to colocalize in large vesicles in ephrinB2-
expressing cells as well as in NiV-G-expressing cells (Fig. 2B, bottom).
In this experiment, NiV-G was stained intracellularly using an anti-
NiV-G monoclonal antibody (5A7) and a secondary goat-α-mouse
antibody conjugated with Alexa568 (red), but identical results were
obtained with NiV-G.mRFP (not shown).
The intracellular vesicles containing ephrinB2 and NiV-G trafﬁc to the
lysosomes
Time-lapse microscopy of CHO cells expressing ephrinB2-eGFP
and NiV-G shows trafﬁcking of incoming vesicles towards the center
of the cell (Video S1). As a particular type of endocytic vesicle – the
macropinosome – has been shown to trafﬁc and fuse with lysosomes
(Racoosin and Swanson, 1993), we decided to investigate whether
this fate befell intracellular vesicles containing ephrinB2 and NiV-G.
To determine this, CHO-K1 cells co-expressing ephrinB2.eGFP and
NiV-G tagged with eCFP were stained with Lysotracker Red, a dye
speciﬁc for the lysosomal compartment. The majority of vesicles
containing both ephrinB2-eGFP (green) and NiV-G-eCFP (cyan-blue)
co-stained with Lysotracker (red) (Fig. 3). The enlargement (Fig. 3,
right) shows typical lysosomes (indicated by arrows) in proximity
with giant intracellular vesicles containing ephrinB2 and NiV-G.
Expression of eCFP-tagged NiV-G was veriﬁed by ﬂow cytometry and
its fusion promotion capacity by co-expression with NiV-F (Figs. S1A
and B). Lamp1 is a membrane protein marker of late endosomes/
lysosomes and similar results were obtained with an anti-Lamp1
antibody/Alexa568 staining (Fig. S6).
Taken together, our results strongly suggest that the intracellular
vesicles containing ephrinB2 and NiV-G are endocytic – possibly
macropinocytic – and trafﬁc to the lysosomes.
VLPs expressing NiV-G or NiV-G/F/M enter cells by the same mechanism
as NiV-G
We next wanted to investigate whether the interaction between
NiV-G and ephrinB2 would allow whole virus to enter by this
endocytic mechanism but were unable to make confocal microscope
studies with live NiV outside of the BSL-4 laboratory. To overcome this
difﬁculty, we generated virus-like particles (VLPs) expressing NiV-G,
either alone or in combination with NiV-F and NiV-M. It has been
shown that expression of individual NiV proteins (for example NiV-G)
from plasmids can drive the formation of VLPs that are released into
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Fig. 3. EphrinB2 and NiV-G colocalize in large vesicles that trafﬁc to lysosomes. CHO cells co-expressing ephrinB2.eGFP and NiV-G.eCFP were treated with Lysotracker Red 24 h p.t.,
ﬁxed and analyzed by confocal microscopy. Arrows indicate typical lysosomes. The image on the right is an enlargement of the merged image on the left, bottom panel. Scale bar:
20 μm.
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expression of NiV-G and NiV-F together with NiV-M leads to the
production of VLPs that have the size and characteristics of authentic
virus (Patch et al., 2007). It was particularly important to include NiV-
F to study if VLPs containing the two NiV glycoproteins would fuse
with the plasma membrane rather than enter endocytically. Thus, a
western blot was made to conﬁrm the presence of NiV-G and NiV-F in
the latter VLPs (Fig. S4). We used the Patch protocol (Patch et al.,
2007) as a basis to produce the VLPs which, labeled with octadecyl
rhodamine B (R18) a lipophilic red ﬂuorescent membrane dye,
were added to cells expressing either eGFP or ephrinB2-eGFP (Fig. 4).
CHO-K1 cells expressing eGFP did not bind NiV-G-expressing VLPs
(Fig. 4A), whereas binding as well as internalization of VLPs was
observed with ephrinB2-expressing cells (Figs. 4B and C). VLPs were
found in association with ﬁlopodia and in large intracellular vesicles
where they colocalizedwith ephrinB2-eGFP (Fig. 4B). In later stages of
the uptake process, ephrinB2-eGFP and NiV-G-containing VLPs
colocalized entirely in large intracellular vesicles (Fig. 4C). Similar
results were obtained with VLPs produced by the co-expression of
NiV-G, NiV-F and NiV-M, with no evidence of R18 coloration of the
plasma membrane (Fig. 4D). These results led us to hypothesize that
NiV can enter cells via an endocytic mechanism.
Mutation of ephrinB2 residues responsible for interaction with EphB4
abrogates NiV entry
Interestingly, ephrinB2 and its cognate receptor EphB4 are also
co-endocytosed into intracellular vesicles following their interactionFig. 2. Co-expression of NiV-G and ephrinB2-eGFP leads to the latter's internalization. (A) C
pcDNA3.1-NiV-G.mRFP, pcDNA3.1-NiV-G(E533Q).mRFP or pcDNA3.1-EphB4.mRFP. Cells we
line quantiﬁed. (B) Populations of CHO cells expressing either eGFP (upper panel) or ephrinB
co-cultivated for 24 h prior to NiV-G staining of ﬁxed permeabilized cells and confocal micro
the right hand side are enlargements of the images on the left. Scale bar: 15 μm.on opposing plasma membranes (Marston et al., 2003). We
conﬁrmed this by tagging mEphB4 with mRFP and showing that
it is co-endocytosed with ephrinB2 in the same manner as NiV-G
(Fig. 2). This result led us to hypothesize that NiV could gain entry
into the host cell by NiV-G mimicking EphB4's interaction with
ephrinB2. To test this, we investigated the effect on NiV entry of
mutating residues in the solvent-exposed G–H loop of ephrinB2
shown in a co-crystallization study (Chrencik et al., 2006) to be
responsible for the interaction with EphB4. To evaluate this, we
used NiV cell–cell fusion as a read-out for NiV entry. Cell–cell fusion
(syncytia formation) is the hallmark of NiV infection and is
dependent upon viral entry. If the virus enters, by whatever
mechanism, viral replication ensues and de novo synthesized NiV
glycoproteins G and F accumulate in the infected cell's plasma
membrane inducing syncytia formation by fusion with surrounding
cells. Quantiﬁcation was made by expressing the number of nuclei
present in syncytia as a percentage of the total number of nuclei, as
previously described (Guillaume et al., 2006). To ensure that the
mutations do not have an inhibitory effect on the viral fusion
process per se, we also tested their effect on cell–cell fusion induced
by the viral glycoproteins G and F expressed from plasmids. The
expression and localization of all ephrinB2 mutants was veriﬁed by
ﬂow cytometry and conventional microscopy (Figs. S2A and B).
If NiV-Gmimics EphB4, mutations in the G–H loop should abrogate
the interaction ephrinB2/NiV-G blocking in turn NiV entry and NiV-
induced cell–cell fusion. We found that this was indeed the case. Two
single mutations, F120A and W125A, reduced cell–cell fusion (not
shown) whereas the quadruple mutation of F120, N123, W125 andHO cells were transfected with 1 μg of peGFP-N1-ephrinB2 and either 1 μg pcDNA3.1,
re then observed by confocal microscopy and the ﬂuorescence proﬁle along the yellow
2-eGFP (lower panel) were mixed with a population of CHO cells expressing NiV-G and
scopic analysis for trans-internalization of ephrinB2-eGFP and NiV-G-mRFP. Images on
Fig. 4. NiV-G-containing VLPs are internalized into large vesicles in ephrinB2-expressing cells. Virus-like particles (VLPs) produced from CHO cells expressing NiV-G were labeled
with the ﬂuorescent membrane dye R18 and added to CHO-K1 cells expressing either eGFP or ephrinB2.eGFP for 1 h at 37 °C. After extensive washing, cells were ﬁxed and analyzed
by confocal microscopy to determine the localization of the VLPs. (A) NiV-G-expressing VLPs do not localize in eGFP-expressing CHO cells. (B) NiV-G-expressing VLPs bind to the
ﬁlopodia of ephrinB2-eGFP-expressing cells and (C) are internalized. (D) The same experiment performed with VLPs containing NiV-M, NiV-F and NiV-G.
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303O. Pernet et al. / Virology 395 (2009) 298–311L127 to alanine resulted in an abrogation of fusion (Figs. 5A and B).
These results demonstrate that the same domain of the G–H loop of
ephrinB2 is responsible for the interactionwith both EphB4 andNiV-G.
Endocytic entry by NiV does not require low pH
We next used the lysomotropic drug chloroquine (CQ), which
raises the pH of late endosomes and lysosomes, to investigate
whether the potential endocytic entry by NiV is dependent (as is
the case for the vast majority of viruses that enter by receptor-
mediated endocytosis) on the acidic conditions found in late
endosomes and lysosomes. We found that 100 μM CQ reduced the
number of NiV plaques in the plaque assay by 100% but importantly
cell–cell fusion induced by transient co-expression of the NiV
glycoproteins was also completely abrogated (not shown). Interest-
ingly, further investigation revealed that NiV glycoproteins were
present in the plasma membrane of the infected cells (Fig. S5) treated
with CQ. This suggests that low pH is not required to allow NiV to exit
from the endocytic vesicle and replicate but that cleavage of the NiV-F,
catalyzed by the low pH requiring protease cathepsin L (Pager et al.,
2006), is inhibited under these conditions. Our results conﬁrm and
extend the results of a recent study (Porotto et al., 2009) which
identiﬁed CQ as an inhibitor of henipavirus replication via a high-
throughput screening assay using recombinant vesicular stomatitis
virus (VSV) pseudotyped with HeV-G and NiV-F.
Interaction of NiV-G with ephrinB2 induces phosphorylation of tyrosine
residues in ephrinB2's cytoplasmic tail
The cytoplasmic tail of ephrinB2 mediates reverse signaling via
protein–protein interactions with intracellular proteins (Cowan and
Henkemeyer, 2001; Lu et al., 2001). Upon interaction with Ephs,
ephrins become phosphorylated at cytoplasmic tyrosine residues
within the 22 residue region between residues 301 and 322 which
allows the recruitment of the adaptor protein Grb4 that transduces
the signal to downstream signaling cascades regulating cytoskeleton
dynamics (Cowan and Henkemeyer, 2001; Holland et al., 1996). We
thus investigatedwhether the contact of NiV-Gwith ephrinB2 induces
the phosphorylation of tyrosine residues in ephrinB2's cytoplasmic
tail. We did this by co-expressing NiV-G.mRFP and ephrinB2-eGFP in
CHO-K1 cells and then staining with an α-phosphotyrosine antibody.
The quantiﬁcation trace shows that phosphotyrosine staining only
occurred in vesicles in which ephrinB2 and NiV-G colocalizedwhereas
in cells not transfected with NiV-G phosphotyrosine staining was
scattered in small punctuations (Fig. 5C). These results suggest the
possibility that ephrinB2 cytoplasmic domain tyrosines are phos-
phorylated following contact with NiV-G.
A single tyrosine mutation (Y304F) in the ephrinB2 cytoplasmic region
virtually abrogates NiV entry
We next investigated whether phosphorylation of ephrinB2
following interaction with NiV-G was relevant to entry of the whole
virus. To investigate whether tyrosine residues present in the
ephrinB2 cytoplasmic tail play a role in NiV entry, we ﬁrst truncated
ephrinB2's cytoplasmic tail at serine268. By using cell–cell fusion as a
read-out for NiV entry, we found that this truncation drastically
reduced NiV entry, and hence fusion. However, this truncation did not
effect cell–cell fusion induced by transient co-expression of the NiV
glycoproteins (Figs. 5A and B).
Next, all six tyrosine residues present in the cytoplasmic tail were
mutated individually to phenylalanine (which lacks the hydroxyl
group on the phenyl ring that allows tyrosine to be phosphorylated).
Mutation of the two tyrosine residues present at the C-terminus, Y330
and Y331, had no effect (Figs. 5A and B) and a similar result was
obtained mutating Y311, Y316 and Y252 (not shown) but the Y304Fmutation caused a 98% reduction in NiV-induced cell–cell fusion
without having any negative effect on cell–cell fusion induced by
transient co-expression of the NiV glycoproteins (Figs. 5A and B).
Furthermore, we found that the number of NiV-G/ephrinB2 vesicles
staining positive for phosphotyrosine was more than 90% reduced in
CHO cells expressing the Y304Fmutant of ephrinB2 rather than thewt
protein (Fig. 5D). The quantiﬁcation graph conﬁrms that strong
localization of ephrinB2 (green) and α-phosphotyrosine (blue) only
occurs where NiV-G (red) ﬂuorescence increases (Fig. 5C Graph).
Interestingly, the Y304F mutant still localizes with NiV-G but cannot
be phosphorylated (phosphotyrosine signal absent) or internalized
into large vesicles (Figs. 5C and D). These results strongly suggest that
phosphorylation of Y304 plays an important role in NiV entry.
If NiV entry is dependent upon phosphorylation of tyrosines in the
ephrinB2 cytoplasmic tail, this raises the possibility of blocking NiV
entry by inhibiting tyrosine kinase activity. We thus examined the
effect of the broad-spectrum tyrosine kinase inhibitor genistein using
a plaque assay. We found that 50 μM of genistein resulted in a
statistically signiﬁcant reduction (22%; pb0.05) in the number of NiV
plaques (Fig. 6A) but had little effect on cell–cell fusion induced by
transfection of plasmids expressing NiV-G and NiV-F (Fig. 6B).
Although the pleiotropic and toxic nature of this broad-spectrum
inhibitor has to be taken into account, these results imply that
tyrosine kinase activity plays a role in NiV entry.
Taking our results together with the Klein group's study of EphB-
ephrinB bi-directional endocytosis (Zimmer et al., 2003) led us to
hypothesize that the endocytic pathway used by NiV for entry could
be macropinocytosis. We thus tested the effect of a number of known
inhibitors of viral entry by macropinocytosis (Mercer and Helenius,
2009) on the entry of NiV.
Dominant-negative mutants of Rac1 and Cdc42 reduce cell–cell fusion
induced by NiV but the RhoA dominant-negative mutant has no effect
The Rho subfamily small GTPases Rac1 and Cdc42, whose
expression induces the production of lamellipodia and ﬁlopodia
respectively, have been implicated in the control of macropinocytosis
(Garrett et al., 2000; West et al., 2000). In a preliminary investigation,
we tested the effect of Toxin B (from Clostridium difﬁcile) a mono-
glucosyltransferase known to inhibit Rho subfamily GTPases
(Aktories and Barbieri, 2005) on NiV entry. We found that 80 mM
Toxin B reduced the number of NiV plaques by 50% (Fig. 6A) but had
little effect on cell–cell fusion induced by transient co-expression of
the NiV glycoproteins (Fig. 6B). However, for the reason that Toxin B
probably has a pluripotent effect on cells, we targeted Rac1 and Cdc42
directly. According to a recent review on viral entry by macro-
pinocytosis (Mercer and Helenius, 2009), infection by macropinocy-
tosis depends upon Rac1 and Cdc42 but not RhoA.We found this to be
the case. Expression of the dominant-negative mutant of RhoA had no
effect on NiV-induced cell–cell fusion but expression of the
dominant-negative mutants of Rac1 or Cdc42 led to a reduction of
by 46% and 53%, respectively (Fig. 6C). In contrast, the Rac1 and Cdc42
mutants had no or minimal effect on cell–cell fusion induced by
transient co-expression of the NiV glycoproteins (Fig. 6C). These
results give strong support to the hypothesis that NiV entry occurs via
macropinocytosis.
PI(3)K inhibitors reduce NiV entry
As Ras activation by receptor tyrosine kinases initiates the
phosphatidylinositol-3-kinase (PI(3)K) signaling pathway which
modulates the closure of macropinosomes, the PI(3)K inhibitors
wortmannin and LY294002 should have an effect on viral entry if this
occurs by macropinocytosis (Mercer and Helenius, 2009). We found
that this was indeed the case: wortmannin and LY294002 reduced the
number of NiV plaques in our plaque assay by 65% and 48%,
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Fig. 6. NiV entry is dependent on macropinocytosis. Vero cells were either (A) infected with NiV or (B) co-transfected with phCMV-NiV-G and phCMV-NiV-F in the presence or
absence of 100 μM5-(N-ethyl-N-isopropyl) amiloride (EIPA), 80 μMToxin B (Tox B), 50 μMgenistein, 100 μM LY294002, 50 μMBlebbistatin (Blebb), 50 nMWortmannin (Wort) and
2 μM Latrunculin A (LatA). (A) Virus entry was evaluated by plaque assay after 72 h p.i. and (B) fusion activity by cell–cell fusion assay 48 h p.i. (C) Dominant-negative mutants
N17Rac1-eGFP, N17Cdc42-eGFP or N19RhoA were expressed in Vero cells 24 h before infection by NiV or co-transfected with NiV-G and NiV-F. Syncytia formation was quantiﬁed as
described above 24 h p.t. or 48 h p.i., respectively. Experiments were performed in triplicate and data are represented as the standard deviation of themean. (D) FITC-Dextran uptake
by NiV-G-expressing Vero cells is inhibited by EIPA in a ﬂuid uptake assay. Vero cells, expressing either NiV-G, treated with PMA (positive control) or left untreated, were incubated
with FITC-Dextran for the indicated time points. Uptake of FITC-Dextran was analyzed by ﬂow cytometry and is indicated by the mean ﬂuorescence intensity (MFI). One
representative experiment out of three is shown. (E) EIPA dose effect on virus entry was evaluated by plaque assay after 72 h p.i.
305O. Pernet et al. / Virology 395 (2009) 298–311respectively (Fig. 6A). Moreover, we found that the small molecule
blebbistatin, a speciﬁc inhibitor of myosin II (required to effect the
closure of macropinosomes) reduced NiV plaque numbers by 54%
(Fig. 6A).
Latrunculin A strongly inhibits NiV entry
Macropinosome formation is an actin-based process. Thus, viral
entry and infection via macropinocytosis should be sensitive to
inhibitors of actin dynamics such as the compound Latrunculin A
(Mercer and Helenius, 2009). We found that Latrunculin A, which
inhibits the polymerization of actin, reduced the number of NiV
plaques in our plaque assay by 83% (Fig. 6A). This result provides
critical evidence that NiV entry occurs via macropinocytosis.
Amiloride abrogates NiV entry
Finally, we tested the effect of amiloride a speciﬁc inhibitor of
macropinocytosis which acts by blocking the Na+/H+ exchange
required for macropinocytosis to occur (West et al., 1989). Fluid
uptake by cells via macropinocytosis can be monitored by the use of
the ﬂuid phase marker 70-kDa dextran (Mercer and Helenius, 2008).
We hypothesized that if the NiV-G/ephrinB2 interaction inducesFig. 5. NiV entry requires tyrosine 304 in the ephrinB2 cytoplasmic domain. (A) CHO cells tra
residues mutated (F120, N123, W125, L127/AAAA), ephrinB2 lacking the cytoplasmic tail
YY330/1FF). Cells were either infected with NiV (200 PFU/well) 24 h p.t. (upper panel) or co
48 h p.i. or p.t. for syncytia formation. (B) Cell-to-cell fusion in Fig. 4A experiments was qua
three randomly selected images. Experiments were performed in triplicate and data are rep
interaction with NiV-G. Upper panels: CHO cells expressing ephrinB2-eGFP with or without
and a secondary antibody, goat-α-mouse-Alexa647 and then analyzed by confocal microsco
(D) Effect of ephrinB2 Y304F mutation on colocalization of ephrinB2 and anti-phosphotyro
phosphotyrosine+ vesicles per cell was counted. For each set, 10 cells were analyzed and dmacropinocytosis, the transient expression of NiV-G in cells permis-
sive for NiV should result in an uptake of 70-kDa dextran that would
be sensitive to ethyl isopropyl amiloride (EIPA). We found that this
was indeed the case: expression of NiV-G in Vero cells resulted in a
steady increase in the uptake of 70-kDa FITC-dextran over 60 min as
measured by ﬂow cytometry and treatment with 100 μM EIPA
reduced this uptake by more than 35% (Fig. 6D). Moreover, we found
that 100 μM EIPA reduced NiV plaque numbers in a plaque assay by
100% (Fig. 6A) but had minimal effects on cell–cell fusion induced by
the transient co-expression of the NiV glycoproteins (Fig. 6B). When
we investigated the effect of lower EIPA concentrations in the plaque
assay, we found that the number of plaques (pfu) formed was
inversely proportional to the EIPA concentration (Fig. 6E).
Discussion
The major conclusion from this study is that NiV can enter the host
cell by receptor-mediated endocytosis and that the particular endocytic
pathway used is macropinocytosis. To our knowledge, this is the ﬁrst
demonstration of paramyxovirus entry by macropinocytosis—the vast
majority are assumed to enter the host cell by fusion (at neutral pH) at
the plasma membrane. Moreover, our results obtained with the
lysomotropic drug chloroquine suggest that the endocytic pathwaynsfected to express ephrinB2-eGFP (non-mutated), ephrinB2-eGFP with four G–H loop
(Δ268) or with cytoplasmic tail tyrosine residues mutated to phenylalanine (Y304F,
-transfected with phCMV-NiV-G and phCMV-NiV-F (lower panel). Cells were examined
ntitatively analyzed and is expressed as the ratio of nuclei in syncytia to total nuclei in
resented as the standard deviation of the mean. (C) ephrinB2 is phosphorylated upon
NiV-G-mRFP were ﬁxed, permeabilized, stained with an α-phosphotyrosine antibody
py. Lower panels: the same experiment made with ephrinB2.Y304F. Scale bar: 15 μm.
sine, with and without NiV-G, in intracellular vesicles. The number of ephrinB2+/anti-
ata are represented as the standard deviation of the mean.
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few viruses are known to utilize. Our results suggest that NiV achieves
endocytic entry by virtue of its attachment protein NiV-G mimicking
the interaction of EphB4 with its ligand ephrinB2. Importantly, both
EphB4 and ephrinB2 have receptor tyrosine kinase (RTK) activity and
are implicated in numerous cellular processes important in develop-
ment. Notably, they are expressed respectively on venous and arterial
endothelial cells. During vasculogenesis, their interaction ensures that
repulsion rather than adhesion occurs when a venous cell encounters
an arterial cell. Repulsion is achieved by bi-directional trans-
endocytosis of the intact EphB4-ephrinB2 complex that is concomitant
with depolymerization of the actin skeleton and retraction of ﬁlopodia
and lamellipodia. This mechanism strongly resembles receptor-
mediated macropinocytosis (Wilkinson, 2003).
Recent publications have already hinted that endocytosis is
involved in Henipavirus replication although the mechanism by
which this is achieved and indeed its signiﬁcance, have remained
obscure. The ﬁrst indication was the ﬁnding that the protease
Cathepsin L – which localizes to low pH late endosomes and
lysosomes – is responsible for the proteolytic processing of both the
HeV-F protein (Pager and Dutch, 2005) and NiV-F (Himanen et al.,
2001). Another study using transient expression of HeV glycoproteins
in Vero cells found that expression of dominant-negative mutants of
GTPases Rac1 and Cdc42 had little effect on cell–cell fusion induced by
plasmids expressing NiV-G and NiV-F (Schowalter et al., 2006), but
these authors did not investigate the effect of these mutants on cell–
cell fusion induced by the virus. Finally, a recent publication
(Diederich et al., 2008) reported that NiV can be endocytosed but
the authors – who did not test any inhibitors of receptor-mediated
macropinocytosis and did not demonstrate NiV-G-induced ephrinB2
downregulation – concluded that endocytosis is ‘deﬁnitely not
required for the NiV entry process’. We believe that this conclusion
is emphatically contradicted by our results.
In effect, our preliminary ﬁndings show that when ephrinB2 and
NiV-G are expressed on opposing cells, both proteins are trans-
endocytosed into intracellular vesicles which are then transported
towards the lysosomes. Not only does this demonstrate, for the ﬁrst
time, that the NiV receptor is internalized from the cell surface upon
interaction with NiV-G but also suggests that NiV-G can potentially
mimic EphB4's interaction with ephrinB2 and thereby allow NiV to
enter by the same endocytic mechanism. Hitherto, the question of
ephrinB2 downregulation by NiV-G has been controversial. A recent
report (Sawatsky et al., 2007) concluded that both the expression of
NiV-G and NiV infection had no effect on the cell-surface expression of
ephrinB2. We found this result surprising because the closely related
Morbilliviruses internalize their receptors upon infection. Viruses of
the Morbillivirus genus and the Henipavirus genus differ from the
other paramyxoviruses in that they use cellular proteins as receptors
rather than sialic acid and for the Morbillivirus measles virus (MV) it
has been shown that its two known receptors, CD46 and SLAM
(CD150), are downregulated from the cell surface upon infection
(Naniche et al., 1993; Tanaka et al., 2002). Moreover, ephrinB2
downregulation could potentially be responsible for the vasculitis that
characterizes NiV pathogenesis, in particular encephalitis, as vascular
smoothmuscle mural cells require ephrinB2 for their association with
small diameter blood vessels (Foo et al., 2006).
Our ﬁnding that expression of ephrinB2 provokes the formation of
extensive polarized ﬁlopodia was an initial indication that macro-
pinocytosis could be involved in NiV entry. Filopodia are protrusions
of the plasma membrane important not only for cell movement and
tentative encounters with other cells but also – in specialized cell
types such as macrophages and immature dendritic cells – for uptake
of ﬂuid and the entrapment of exogenous antigen (for a review see
(Conner and Schmid, 2002; Klasse et al., 1998; West et al., 1989).
If NiV-G mimics EphB4, the same residues of ephrinB2 should be
responsible for the interaction with both of these proteins. We havedemonstrated that this is indeed the case:mutating ephrinB2 residues
in the solvent-exposed G–H loop that have been shown to be
responsible for interaction with EphB4 in co-crystallization studies
(Kolokoltsov et al., 2007) abrogated syncytia formation by NiV. A
recent co-crystallization study of ephrinB2 and NiV-G (Bowden et al.,
2008) conﬁrms that this stretch of ephrinB2's G–H loop is the binding
site for NiV-G. Signiﬁcantly, by tagging EphB4 with mRFP, we were
able to show that this protein is co-endocytosed with ephrinB2 in the
same manner as for NiV-G conﬁrming the results of the Klein group
(Zimmer et al., 2003). Because Klein's group did not ﬁnd any
colocalization with markers of the clathrin and caveolae pathways,
they speculated that the endocytic mechanism responsible for
ephrinB–EphB endocytosis was either phagocytosis or macropinocy-
tosis, especially as they found that the process was dependent on the
GTPase Rac1 (Zimmer et al., 2003). Taking this into consideration
together with our results, we decided to test the effect of a number of
inhibitors known to disrupt viral entry by macropinocytosis (Mercer
and Helenius, 2009) on NiV entry. Viral entry by macropinocytosis is
dependent both on a multi-branched signaling cascade and cytoskel-
eton dynamics (Mercer and Helenius, 2009). The results obtained
with the Rac1, Cdc42 and RhoA dominant-negative mutants,
wortmannin, LY294002, blebbistatin and in particular Latrunculin A
and the amiloride derivative EIPA provide compelling evidence that
the receptor-mediated endocytic pathway that NiV uses for entry is
macropinocytosis.
Although EIPA abrogated NiV infection, 100% the effect of
amiloride is no longer considered to be the deﬁnitive test for
macropinocytosis (Mercer and Helenius, 2009). However, as macro-
pinocytosis, unlike fusion at the plasma membrane, requires actin
polymerization to allow the necessary changes in cytoskeleton
dynamics our ﬁnding that Latrunculin A gives an 83% inhibition of
NiV infection provides very strong support that macropinocytosis is
involved. It is interesting to note that inhibitors such as genestein and
Toxin B, which are toxic and have pluripotent effects in the cell, show
relatively lower inhibition rates (22% and 50%, respectively) whereas
themore speciﬁc inhibitors give higher inhibition rates. Obtaining less
than 100% inhibition with macropinocytosis inhibitors could be
interpreted as meaning that NiV does not enter exclusively by
macropinocytosis into the cell lines we have used. We advance two
major reasons why we believe that this is not the case. Firstly, as
macropinocytosis is induced via a multi-branched signaling cascade
(Mercer and Helenius, 2009) redundancy could provide an explana-
tion as to why inhibition with certain drugs and dominant-negative
mutants was not total. For example, Rac1 and Cdc42 dominant-
negative mutants gave reductions in NiV infection by 46% and 53%,
respectively. However, although Cdc42 is regarded to be responsible
for ﬁlopodia formation (Garrett et al., 2000), ﬁlopodia are still present
on cells which do not express Cdc42 (Czuchra et al., 2005). Secondly,
the use of macropinocytosis for entry by NiV is supported by our
ﬁnding that the cytoplasmic domain of ephrinB2 is required for entry—
but signiﬁcantly, not for viral spread (syncytia production).
Macropinocytosis is induced by a receptor tyrosine kinase (RTK)-
dependent signaling cascade (Mercer and Helenius, 2008) and
importantly the NiV receptor ephrinB2 has RTK activity. If NiV entry
is dependent uponmacropinocytosis the phosphorylation of ephrinB2
upon interaction with NiV would thus appear to be a necessity. Our
results show that the interaction of NiV-G with ephrinB2 indeed
induces the phosphorylation of the latter and that this involves a
single tyrosine (Y304) in ephrinB2's cytoplasmic domain. Signiﬁcant-
ly, mutation of this single tyrosine to phenylalanine abrogates NiV
entry. However, in this respect it has recently been reported that
ephrinB2's cytoplasmic tail is not required for NiV entry (Thiel et al.,
2008). If true, this would deal a near-fatal blow to our hypothesis of
NiV entry by macropinocytosis but close examination of a western
blot in this article reveals that there is a potential problem with their
cytoplasmic tail-deleted ephrinB2. The western blot appears to show
307O. Pernet et al. / Virology 395 (2009) 298–311that the untruncated ephrinB2 has a molecular weight (MW) of
around 45 kDa whereas that of the truncated ephrinB2 appears to be
close to 40 kDa. However, the MW of untruncated ephrinB2 is in fact
37 kDa (Masood et al., 2009). We suggest that this size difference
could well be the basis for the difference between our results and
those of the Maisner group, pertaining to the role of ephrinB2's
cytoplasmic tail in NiV entry.
A recent review on virus entry by macropinocytosis (Mercer and
Helenius, 2009) poses the rhetorical question of whether there are
different types of macropinocytosis and if so how do they differ?
According to this review, viruses that enter bymacropinocytosis cause
cytoskeletal rearrangements to occur in the host cell (with the notable
exception of dendritic cells) that lead to rufﬂing and blebbing at the
plasmamembrane. These changes in actin polymerization are induced
by signaling from receptor tyrosine kinases (RTKs) which are
indirectly activated by the virus binding to a plasma membrane
protein. When the small ﬁlopodia or lamellipodia which constitute
the rufﬂes melt back into the plasma membrane they engulf the virus
to enclose it together with extracellular ﬂuid in a macropinosome.We
suggest that NiV entry by macropinocytosis represents a variation of
this because the NiV receptor itself is an RTK and induces the
formation of ﬁlopodia constitutively. Our interpretation of our results
is that rather than inducing ﬁlopodia formation, the interaction with
NiV-G with ephrinB2 triggers a signaling pathway that results in
ﬁlopodia formation being turned off so that they retract and in doing
so engulf the NiV particle (Fig. 7).
An obvious strategic advantage of macropinocytosis over plasma
membrane fusion for viral entry is that – as for other endocyticFig. 7. The entry of NiV by receptor-mediated macropinocytosis. In this hypothetical sche
(Bowden et al., 2008; Chrencik et al., 2006; Cowan and Henkemeyer, 2001; Marston et al., 20
red and their potential site of action indicated. (For interpretation of the references to colomechanisms – no trace of the virus is left at the plasma membrane to
attract the attention of the host immune response. However, further
study will be required to investigate whether our results obtained
with Vero and CHO-K1 cells can be extrapolated to other cell types. In
particular it will be interesting to determine whether NiV entry occurs
in cells such as macrophages and dendritic cells which operate
continuous constitutive macropinocytosis.
Interestingly, our results suggest that the endocytic mechanism
of entry used by NiV does not require low pH. But then why does
fusion not occur at the plasma membrane ? We suggest two possible
explanations for this enigma. First, that in the case of NiV,
endocytosis of the virus could occur more rapidly than plasma
membrane fusion. The second possible explanation that we have
considered is that NiV entry and NiV spread (cell–cell fusion) require
different conformations of NiV-G. We are currently investigating
both of these possibilities.
It is becoming clear that the mere docking of a virus to its cellular
receptor is often insufﬁcient for entry. Viruses have evolved to make
use of the cellular machinery to enter the host cell and a prime
means to do this is via signalization. That virus attachment to
receptors triggers essential intracellular signals has only recently
been appreciated (Marsh and Helenius, 2006). Interestingly, it has
been reported that phosphorylation of Y304 of ephrinB2 confers
high-afﬁnity binding to the SH2 domain of the SH2/SH3 adaptor
protein Grb4 which transduces signals via its SH3 domains (Su et al.,
2004). As Grb4 transduces signals to downstream effectors of
cytoskeleton dynamics RacI and Cdc42, this provides a plausible
explanation of how NiV-G-induced ephrinB2 phosphorylationmatic, the results presented in this study are summarized with the results of others
03; Su et al., 2004; Zimmer et al., 2003). Various inhibitors of this pathway are shown in
ur in this ﬁgure legend, the reader is referred to the web version of this article.)
308 O. Pernet et al. / Virology 395 (2009) 298–311induces macropinocytosis. This is summarized in our schematic
model for NiV entry shown in Fig. 7.
It is conceivable that our results can be generalized for those
viruses whose receptor (i) is downregulated upon infection, (ii) is a
signaling protein and (iii) induces the production of ﬁlopodia. Human
adenovirus subverts CtBP1-controlled macropinocytosis to gain entry
(Amstutz et al., 2008), but although the actual mechanism by which
macropinocytosis is subverted was not deduced by these authors,
interestingly, this adenovirus uses CD46 as a receptor. CD46 is also a
receptor for MV. That MV has the capacity to enter cells by
macropinocytosis has been reported (Crimeen-Irwin et al., 2003)
but this process was suggested to function to remove fusion-
incompetent virus. Interestingly, we have discovered that CD46 – as
well as MV's other cellular receptor SLAM (CD150) – induces the
formation of ﬁlopodia extremely similar to those induced by ephrinB2
(Kweder and Buckland, unpublished results). CD46 is used as a
receptor by other viruses such as human herpes virus 6 and certain
bacteria such as Neisseria spp (Liszewski et al., 2005). Moreover, for
Neisseria gonorrhoeae, cell entry has been shown to occur by macro-
pinocytosis (Zenni et al., 2000) and that CD46 is phosphorylated at
tyrosine residue 354 upon infection (Lee et al., 2002). Furthermore, a
cellular protein to which oncolytic MV has been retargeted is EGFR
(Nakamura et al., 2005). This choice was perhaps serendipitous as it
appears to have been made, not because of EGFR's capacity to be
macropinocytosed (following EGF binding) but for EGFR's frequent
overexpression on human cancer cells.
In conclusion, the data we have accumulated provides convinc-
ing evidence that NiV entry occurs by macropinocytosis in the cell
lines we have studied. Set against the present lack of NiV vaccines
and the unlikelihood of their future development due to commercial
considerations, the discovery that NiV can enter by this endocytic
mechanism gives important new hope that a low-cost alternative
antiviral strategy can potentially be developed against this deadly
virus. In this regard, amiloride and CQ are particularly attractive
candidates as they have both been long utilized in human medicine
for treating hypertension and malaria, respectively. We are currently
conducting trials in our P4 laboratory to evaluate the capacity of
both of these drugs to block NiV infection in our animal model, the
hamster.
Materials and methods
Cells
Chinese hamster ovary (CHO-K1) cells (# ACC110 obtained from
DSMZ) were maintained in F12 medium containing 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin, 1 U/ml Fungizon and 10 mM HEPES. VeroE6 cells (African
green monkey kidney ﬁbroblast) were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) containing 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin, 1 U/ml Fungizon and 10 mM HEPES. All cell culture reagents
were obtained from Invitrogen. Typically, 5×105 CHO or 2.5–5×105
Vero cells were seeded per well of a 6-well culture plate prior to
transfection or infection.
Production of mutants and fusion proteins
Site-directed mutagenesis was performed as previously described
(Guillaume et al., 2006). The NiV-G coding sequence was ampliﬁed
by PCR (FastStart; Roche) and inserted into the peCFP-NI (enhanced
cyan ﬂuorescent protein) plasmid (Clontech) between the BsrGI and
NotI restriction sites or between the NotI restriction sites of the
NotI-modiﬁed pcDNA3-mRFP (monomeric red ﬂuorescent protein)
plasmid. NotI-modiﬁed pcDNA3-mRFP is a pcDNA3-mRFP (Addgene)
plasmid with an additional NotI site 8 bases before the EcoRIrestriction site. The murine EphB4 (a gift from Ralf H. Adams, CRUK
London) was cloned between the HindIII and BamHI sites of pcDNA3-
mRFP. The plasmids phCMV-NiV-G, phCMV-NiV-G E533Q and
phCMV-NiV-F have been previously described (Guillaume et al.,
2006). The human ephrinB2 DNA sequence was cloned from the
commercially available expression plasmid phCMV6-XL4-hefnB2
(Origene) and inserted into the peGFP-NI (enhanced greenﬂuorescent
protein) plasmid (Clontech), between the BglII and SalI sites. The
human CD46 DNA sequence was cloned from plasmid pgpt.CD46
(Masse et al., 2004) and inserted into peGFP-NI (Clontech), between
the BglII and SalI sites. The mutated plasmids were ampliﬁed and
puriﬁed as described previously (Masse et al., 2004). Mutations were
introduced using QuickChange kit (Qiagen, France) according to the
manufacturer's instructions. All mutations were veriﬁed by DNA
sequencing. Primer sequences are available on request.
Transfections
Cells were transfected in 1 ml OptiMEM medium containing
plasmid DNA and 1% Lipofectamine (both Invitrogen). For single and
double transfections, 1 μg of each plasmid was used (unless indicated
otherwise). For triple tranfections, 1 μg of phCMV-NiV-G, 0.5 μg of
phCMV-NiV-F and 0.25 μg of peGFP-N1-ephrinB2 or its mutants were
transfected. After 5–7 h incubation at 37 °C, the cells were washed and
fresh medium added.
Infections
As NiV is a BSL class 4 agent, infections were performed in the Jean
Mérieux BSL-4 laboratory, Lyon, France. NiV (isolate UMMC2,
GenBank accession number AY029768.1) isolated from the cerebro-
spinal ﬂuid of a patient was a generous gift from Kaw Bing Chua
(University of Malaya, Kuala Lumpur, Malaysia). Virus was grown and
titrated in Vero cells, and a stock was made on the seventh passage on
Vero cells following virus isolation. Vero cells or transfected CHO cells
were infected with 200 PFU NiV per well for 45 min at 37 °C using a
virus stock diluted in 1 ml of non-supplemented DMEM. Infection
media were then removed and fresh medium added. Images were
taken 48 h later.
Microscopy analysis
Transfected cells, in D-PBS supplemented with MgCl2 and CaCl2,
were observed using a Zeiss Axiovert 200M microscope. Confocal
microscopy analyses were performedwith either a Leica SP5 or a Zeiss
Confocal Axiovert100M LSM510 microscope. Time-lapse analyses
were performed using a Zeiss Time-lapse Axiovert 100M microscope
at 37 °C and 5% CO2. Cells were analyzed after the indicated time
points p.t. or p.i. Microscopy data were analyzed using ImageJ
freeware and Leica LAS AF lite software.
Cellular and immuno-staining
Cells cultivated on LabTek slides (or on coverslips) were washed
with PBS supplemented with CaCl2 and MgCl2. To detect NiV-G, cells
were ﬁxed with 4% PFA, permeabilized with PBS–0.25% Triton X-100
and immuno-stained using a monoclonal mouse-α-NiV-G antibody
(clone 5A7, generated in our laboratory by V. Guillaume) diluted
1:250 and a secondary goat-α-mouse antibody conjugated with
Alexa568 (diluted 1:500, Molecular Probes). To localize ephrinB2 on
CHO-K1 cells (Fig. S3), soluble mEphB4-Fc was stained with goat anti-
human antibody conjugatedwith Alexa 568 (diluted 1:500;Molecular
Probes). For lysosome staining, cells were treated with 50 nM
Lysotracker Red DND 99 (Molecular Probes) for 20 min at 37 °C,
washed twice before ﬁxation with cold 4% PFA for 10 min at room
temperature and mounting in Faramount Mounting Medium (Dako).
309O. Pernet et al. / Virology 395 (2009) 298–311Alternatively, cells were ﬁrst ﬁxed, permeabilized with 0.25% PBS–
Triton X-100 and then stained with 1:200 diluted polyclonal murine
anti-lamp1 antibody (Santa Cruz, CA; a kind gift from D. Muriaux)
followed by 1:500 diluted goat-α-mouse antibody conjugated with
Alexa568 (Molecular Probes). Tyrosine phosphorylation was detected
in PFA-ﬁxed cells using a mouse-α-phosphotyrosine antibody (clone
P66, Sigma) diluted 1:1000 in PBS supplemented with 1% BSA and
0.33% saponin and a goat-α-mouse antibody conjugated with
Alexa680 (diluted 1:600, Molecular Probes) in BSA–saponin buffer.
Samples were mounted prior to analysis. In some experiments,
mounting medium was supplemented with 0.5% DRAQ5 DNA dye
(Biostatus Limited) or Prolong antifade reagent containing DAPI
(Invitrogen).
Flow cytometry
To determine the expression levels of ephrinB2-eGFP and its
mutants as well as NiV-G and its ﬂuorescently labeled or mutated
versions, CHO-K1 or Vero cells were transfected as described above
and analyzed by ﬂow cytometry after 48 or 24 h p.t., respectively.
Brieﬂy, cells were washed with PBS, detached using trypsin and
washed in 1 ml FACS buffer (0.5% bovine serum albumin and 0.02%
sodium azide in D-PBS). Cells expressing NiV-G or one of its derivates
were ﬁxed for 10 min in 4% PFA (in PBS), washed and immuno-
stained using 5A7 monoclonal mouse-α-NiV-G antibody diluted
1:200 in FACS buffer followed by a goat-α-mouse antibody
conjugated with ﬂuorescein isothiocyanate (FITC, Dako) diluted
1:100 in FACS buffer for 30 min at 4 °C each. Cells were analyzed
using a FACSCalibur 3C cytometer (BectonDickinson) and CellQuest-
Pro Software.
Co-culture assays
First, cells were separately cultivated and transfected as described.
Then cells were detached with trypsin and re-seeded for co-culture at
a ratio of 40:60 (ephrinB2-expressing cells:NiG-expressing cells) on a
cover slide for 24 h. Cells were ﬁxed, immuno-stained for NiV-G and
mounted as described above for subsequent analysis by confocal
microscopy.
VLP assay
VLPs were produced, following the protocol of Patch et al. (2007)
by transfection of CHO-K1 cells with phCMV-NiV-G or phCMV-NiV-G
+ phCMV-NiV-F+phCMV-NiV-M for 36 h. VLP-containing cell
culture supernatants were stained with 1 μg/ml R18 for 1 h on a
shaker at RT and then centrifuged (10 min, 3000×g at 4 °C).
Supernatants were diluted in up to 3 ml NTE buffer (100 mM NaCl;
10 mM Tris–HCl, pH 7.5; 1 mM EDTA), loaded onto a 1-ml 20%
sucrose cushion and ultra-centrifuged for 2 h at 150,000×g at 4 °C
(Himac CS 150GX ultra-centrifuge with an S80AT3 rotor). Pellets
were washed with NTE buffer and re-ultra-centrifuged. Pellets were
ﬁnally resuspended in 200 μL NTE buffer. VLP preparations were
added to CHO-K1 cells expressing either ephrinB2-eGFP or eGFP for
1 h at 37 °C. Cells were then washed extensively, ﬁxed, mounted and
analyzed by confocal microscopy. A western blot was made to
conﬁrm the presence of NiV-G and NiV-F in the VLP's. Brieﬂy, the
puriﬁed VLPs were resuspended and reduced in Laemmli buffer
containing 5% β-mercapto-ethanol (Sigma), at 100 °C for 10 min.
Proteins were then separated on SDS–PAGE (12% acrylamide-
bisacrylamide) and transferred onto a PVDF membrane. The NiV
glycoproteins were stained using a murine α-NiV serum (generated
in our laboratory by V. Guillaume) as a primary antibody and then a
rabbit anti-mouse antibody (Dako) conjugated with horseradish
peroxidase (HRP) as secondary antibody. HRP was revealed using an
ECL kit and CL-Exposure ﬁlm (both Pierce).Quantiﬁcation of NiV entry
In this study, two methods have been to quantify the effect of
various inhibitors andmutations on NiV entry and determine its basis:
a cell–cell fusion assay and a plaque assay. Both methods were used in
tests involving viral infection (under BSL-4 conditions), but for
infections due to inherent problems of maintaining monolayer
integrity, only the cell–cell fusion assay was used.
Plaque assay
The 5×105 Vero cells per 6-well culture plate were seeded and
conﬂuent cell layers were infected as described above. After infection,
cells were kept in medium containing 33% carboxymethyl cellulose
(Interchim) supplementedwith inhibitors as indicated. Three days p.i.,
cells were washed with D-PBS, incubated with crystal violet solution
(0.2% crystal violet, 10% formol and 20% ethanol) for 15 min and
subsequently rinsed with water. The number of plaques (syncytia)
was counted and the percentage relative to non-treated cells (set to
100%) calculated. Experiments were performed in triplicate and the
error bars represent the standard deviation between experiments. A
Student's t-test was applied to determine the statistical relevance of
the results obtained with Toxin B and genestein based on the original
plaque counts in three experiments.
Quantiﬁcation of cell–cell fusion
Cell–cell fusion in transfected cells was quantiﬁed as described
previously (Guillaume et al., 2006). Brieﬂy, 24 h p.t. or 48 h p.i.,
respectively, images of three microscope ﬁelds were taken randomly
and the proportion of nuclei in syncytia relative to the total number of
nuclei was determined by counting. Experiments were performed in
triplicates and error bars represent the standard deviation.
Inhibition of macropinocytosis/viral entry
5-(N-Ethyl-N-isopropyl) amiloride (EIPA) (100 mM in DMSO),
Toxin B (10 mM in non-supplemented DMEM), Wortmannin (10 mM
in DMSO), LY294002 (100 mM in DMSO), Blebbistatin (100 mM
in DMSO) and genistein (10 mM in ethanol) stock solutions were
prepared (all Sigma). One hour before infection (or 7 h p.t. for controls
withplasmids), inhibitorswere added to the culturemediumaswell as
to the infection and post-infection media (10× diluted for long-term
lethal inhibitors Latrunculin, Wortmanin LY294002 and Blebbistatin).
Quantiﬁcation of the infection of non-transfected cells was measured
by aplaque assay as describedbelowwhereas for cells transfectedprior
to infection the cell–cell fusion assay was used. Rho GTPases Cdc42,
Rac1 and RhoA were inhibited by their respective N17 dominant-
negative mutants: for the infection assay, 2.5×105 Vero cells were
transfected with 0.4 μg of pEGP-CI-N17Cdc42 or pEGP-CI-N17Rac1
(gifts from P. Jurdic) or pEGP-CI-N19RhoA (a gift from Delphine
Muriaux) in 6-well culture plates and infected 18 h p.t. as described
above. For the fusion assay, 0.4 μg of pEGP-CI-N17Cdc42 or pEGP-CI-
N17Rac1 or pEGP-CI-N19RhoA dominant-negative mutants was
co-transfected with 1 μg of phCMV-NiV-G and 1 μg of phCMV-NiV-F.
Fluid phase uptake analysis
Fluid phase uptake was assessed using a modiﬁed protocol
previously described (Mercer and Helenius, 2008). Vero cells
(5×104 per well) were seeded in 24-well culture dishes and either
transfected with pHCMV-NiV-G the following day or left untreated. At
20 h p.t., all cells were serum starved for 3 h at 37 °C and 5% CO2 before
adding 100 μM EIPA in serum-reduced DMEM (containing 0.1% FCS)
for 1 h. Cells not receiving any EIPA treatment were left in non-
supplemented starvation medium (DMEM+0.1% FCS). For PMA
310 O. Pernet et al. / Virology 395 (2009) 298–311treatment (positive control), cells were incubated in medium
containing 100 μM PMA for 1 h at 4 °C. PMA-treated cells were
washed twice with cold D-PBS and 70-kDa FITC-conjugated Dextran
(Sigma) was added to all cells for 10, 30 or 60 min, respectively.
During the incubation, cells were agitated regularly. Finally, cells were
washed twice with cold PBS, once with low pH buffer (0.1 M sodium
acetate, 0.05 M NaCl, pH 5.5), and then prepared for subsequent ﬂow
cytometric analysis as described above.
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